Journal article
Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users
JK Flynn, GJ Dore, M Hellard, B Yeung, WD Rawlinson, PA White, JM Kaldor, AR Lloyd, RA Ffrench
Journal of Viral Hepatitis | WILEY | Published : 2011
Abstract
The critical events in clearance or persistence of hepatitis C virus (HCV) infection are unknown but likely to be determined early in acute infection. Type 1 and type 2 cytokine production was assessed by HCV peptide ELISpot and multiplex in vitro cytokine production assays in longitudinally collected samples from 20 untreated participants enrolled in the Australian Trial in Acute Hepatitis C (ATAHC); a prospective cohort of acute HCV infection (77% injecting drug users, IDU). Significantly higher interleukin-10 (IL-10) production (P = 0.048), in the relative absence of interferon-gamma (IFN-γ) and IL-2 production, was present early in HCV infection in those who progressed to chronic infecti..
View full abstractGrants
Awarded by National Institute on Drug Abuse
Funding Acknowledgements
We thank Geza Paukovics (Burnet Institute) for assistance with flow cytometry, and Tim Spelman (Burnet Institute) for assistance with statistical analysis. We also thank the subjects enrolled in the ATAHC study. This paper is funded by the National Institutes of Health grant R01 DA 15999, and the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. NCHECR is affiliated with the Faculty of Medicine, University of New South Wales. Roche Pharmaceuticals supplied financial support for pegylated IFN gamma-2a/ribavirin.This study was funded by NIH IROIDA 15999-01. JF was supported by an NHMRC PhD Dora Lush scholarship, and MH was supported by NHMRC and VicHealth Fellowships.RF was supported by NHMRC Industry Fellowship. GD was supported by a NHMRC Practitioner Fellowship.